BWAY Brainsway

BrainsWay to Report First Quarter 2025 Financial Results on May 13, 2025

BrainsWay to Report First Quarter 2025 Financial Results on May 13, 2025

BURLINGTON, Mass. and JERUSALEM, April 29, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, May 13, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time the same day to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information

Date:Tuesday, May 13, 2025
Time:8:30 AM Eastern Time
United States:1-877-300-8521
International:1-412-317-6026
Israel:1-80-921-2373
Conference ID:10198731
Webcast:
  

The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, . Please access the Company’s website at least 10 minutes ahead of the conference call to register.

About BrainsWay

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in Israel and the U.S., BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit .

Contacts:

BrainsWay:

Ido Marom

Chief Financial Officer

Investors:

Brian Ritchie

LifeSci Advisors



EN
29/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Brainsway

 PRESS RELEASE

BrainsWay to Showcase Deep TMS at the 2025 American Psychiatric Associ...

BrainsWay to Showcase Deep TMS at the 2025 American Psychiatric Association Annual Meeting in Los Angeles Exhibit Booth Demonstrations and Participation in Expert Master Course Highlight BrainsWay’s Expanding Role in Psychiatric Care BURLINGTON, Mass. and JERUSALEM, May 01, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, is proud to announce its participation at the American Psychiatric Association (APA) Annual Meeting, taking place May 17–21, 2025, in Los Angeles, California....

 PRESS RELEASE

BrainsWay to Report First Quarter 2025 Financial Results on May 13, 20...

BrainsWay to Report First Quarter 2025 Financial Results on May 13, 2025 BURLINGTON, Mass. and JERUSALEM, April 29, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, May 13, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time the same day to discuss the...

 PRESS RELEASE

BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results ...

BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights Achieved record quarterly sales of $11.4 million in Q4 2024, an increase of 27% compared with Q4 2023 Full year 2024 revenue increased nearly 30% YoY to $41 million Exceeded full year 2024 operating income and Adjusted EBITDA margin guidance Company expects continued strong growth in 2025, with revenue of $49 million to $51 million and further improvement in profit and profitability Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 11, 2025 (GLOBE NEWS...

 PRESS RELEASE

BrainsWay to Present at the Oppenheimer 35th Annual Healthcare MedTech...

BrainsWay to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference BURLINGTON, Mass. and JERUSALEM, March 04, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that management will present virtually at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference at 9:20 AM EST on March 18, 2025. A live webcast of the presentation will be available on the Events & News – Presentations page of the Co...

 PRESS RELEASE

BrainsWay to Report Fourth Quarter and Full Year 2024 Financial Result...

BrainsWay to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025 BURLINGTON, Mass. and JERUSALEM, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its fourth quarter and full year 2024 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, March 11, 2025. The Company will host a conference call and webcast at 8:30 AM...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch